Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

ABSTRACT:

Purpose

To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Design

Cohort within a randomized clinical trial.

Participants

We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.

Methods

Eyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional h

SUBMITTER: Grunwald JE 

PROVIDER: S-EPMC3892560 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature